IF he is on dialysis the issue of nephrotoxicity is really moot. Further damamge will not be an issue.
In the patient with renal impairment there are two major considerations regarding HIV therapy: dosing and nephrotoxicity. Dosing for varying degrees of renal insufficiency have been devisd for 3TC, FTC and tenofovir.
As far as renal toxicity, all HIV therapies are fairly safe. Indinavir can cause nephrolithiasis that can complicate renal function. Tenofovir has been linked to a small change in creatinine clearance over time in patients with advanced HIV infection (J Gallant, et al. Clinical Infectious Diseases, 2005). However, the clinical relevance of such a change remains to be determined.
DW